Compare CBNK & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | SGP |
|---|---|---|
| Founded | 1974 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 650.9M |
| IPO Year | 2018 | 2026 |
| Metric | CBNK | SGP |
|---|---|---|
| Price | $37.63 | $25.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $35.50 | ★ $45.00 |
| AVG Volume (30 Days) | 49.9K | ★ 81.4K |
| Earning Date | 04-27-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 60.85 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.40 | $17.06 |
| 52 Week High | $38.83 | $30.56 |
| Indicator | CBNK | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 65.67 |
| Support Level | $34.40 | $20.95 |
| Resistance Level | $38.83 | $25.83 |
| Average True Range (ATR) | 0.89 | 1.34 |
| MACD | -0.05 | 0.28 |
| Stochastic Oscillator | 61.04 | 77.74 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.